Metrics as of 10/15/2026, 11:23 AM (Berlin time), refresh in progress.
SIGA Technologies, Inc.
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the…
1D
+2.9%
1W
-2.7%
1M
+7.0%
6M
-31.2%
YTD
-47.8%
1Y
-62.1%
2Y
-52.7%
5Y
-55.1%
10Y
+42.4%
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~15% stronger price swings than usual
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 06/11/2012
P/E
-73.17
P/B
1.38
EV/EBITDA
-22.86
RETURN ON EQUITY
7.5%
NET MARGIN
30.4%
DEBT/EQUITY
0
DIVIDEND YIELD
18.8%
AS OF
30/06/2026
FREE FLOAT
57.2%
FLOAT SHARES
41,113,126
AVG. DAILY VOLUME (30D)
635,174
Nabel Gary J.
Nabel Gary J.
DURNAN JAYMIE A
DURNAN JAYMIE A
Nemirovsky Julian
SIGA Technologies, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Diem Nguyen, the company employs around 49 people.
The IPO was on 10/09/1997; the stock trades on NASDAQ under the ticker SIGA.
1 analysts rate the stock, the consensus is Buy (as of 06/11/2012).
This is an external assessment, not a statement by Market Jury.
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 15% stronger than usual.
Yes. The last dividend was US$0.60 per share, ex-date 07/04/2026, paid on 23/04/2026.
The dividend yield is 18.8% (as of 30/06/2026).
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
Clicking "Analyze stock" lets five strategies assess SIGA Technologies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.